Spyre Therapeutics
SYRE
84 hedge funds and large institutions have $328M invested in Spyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 32 reducing their positions, and 11 closing their positions.
186% more call options, than puts
Call options by funds: $340K | Put options by funds: $119K
3% more capital invested
Capital invested by funds: $319M → $328M (+$9.41M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less ownership
Funds ownership: 3.46% → 3.46% (-0%)
9% less funds holding
Funds holding: 92 → 84 (-8)
28% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 32
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.39M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$4.67M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.86M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.71M |
| 5 |
SCM
Sio Capital Management
New York
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.01M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.85M |
| 4 |
Millennium Management
New York
|
-$676K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$434K |
SYRE Hedge Fund Activity: Q1 2021 in Review
84 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2021, worth a combined $328M — up 2.9% from $319M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SYRE and 3 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 23 added.
The largest buyer was Goldman Sachs, adding an estimated $5.39M. The largest seller was Point72 Asset Management, cutting an estimated $10.9M.
- 84 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2021, down from 92 in Q4 2020.
- Funds reported $328M of Spyre Therapeutics stock for Q1 2021, up 2.9% quarter-over-quarter.
- 3 funds opened new Spyre Therapeutics positions in Q1 2021 and 11 closed out, a net change of -8 holders.
- The largest Spyre Therapeutics buyer in Q1 2021 was Goldman Sachs, an estimated $5.39M added.
- The largest Spyre Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2021.